Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): A pooled analysis of 10 studies

Journal of Clinical Psychiatry

Volumn 69, Issue 8, 2008, Pages 1287-1292

  Papakostas, George I ^a,d   Stahl, Stephen M ^b   Krishen, Alok ^c   Seifert, Cheryl A ^a   Tucker, Vivian L ^c   Goodale, Elizabeth P ^c   Fava, Maurizio ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GLAXOSMITHKLINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NORADRENALIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

EID: 49649094322     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0812     Document Type: Article

References (43)

1. Fava M, Alpert JE, Carmin CN, et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med 2004;34(7):1299-1308
2. Regier DA, Burke JD Jr, Christie-Burke K. Comorbidity of affective and anxiety disorders in the NIMH Epidemiologic Catchment Area Program. In: Maser J, Cloninger C, eds. Comorbidity of Mood and Anxiety Disorders, Washington, DC: American Psychiatric Press; 1990:113-122
3. Melartin TK, Rytsälä HJ, Leskelä US, et al. Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study. J Clin Psychiatry 2002;63:126-134
4. Fava M, Rankin MA, Wright EC, et al. Anxiety disorders in major depression. Compr Psychiatry 2000;41:97-102
5. Fava M, Rush AJ, Alpert JE, et al. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatry 2006;51(13):823-835
6. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56(9):395-401
7. Stahl SM, Pradko JF, Haight BR, et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004;6(4):159-166
8. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005;66(8):974-981
9. Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol 2006;16(6):391-402
10. Papakostas GI, Trivedi MH, Alpert JE, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res 2008;42:134-140
11. Stahl SM, Zhang L, Damatarca C, et al. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry 2003;64(suppl 14):6-17
12. Nutt DJ, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol 2007;21(5):461-471
13. Zimmerman M, Posternak MA, Attiullah N, et al. Why isn't bupropion the most frequently prescribed antidepressant? J Clin Psychiatry 2005;66(5):603-610
14. Rush JA, Trivedi MH, Carmody TJ, et al. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology 2001;25(1):131-138
15. Rush AJ, Batey SR, Donahue RMJ, et al. Does pretreatment anxiety predict response to either bupropion SR or sertraline? J Affect Disord 2001;64:81-87
16. Feighner JP, Gardner EA, Johnston JA, et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 1991;52(8):329-335
17. Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997;58(12):532-537
18. Croft H, Settle E Jr, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999;21(4):643-658
19. Coleman CC, Cunningham LA, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999;11(4):205-215
20. Weihs KL, Settle EC Jr, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000;61(3):196-202
21. Coleman CC, King BR, Bolden-Watson C, et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001;23(7):1040-1058
22. Clayton AH, Croft HA, Horrigan JP, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006;67(5):736-746
23. Kennedy SH, Fulton K, Bagby MR, et al. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry 2006;51(4):234-242
24. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354(12):1231-1242
25. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006;189:124-131
26. International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) Guidelines. Available at: http://www.ich.org. Accessed August 15, 2007
27. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
28. Hamilton M. The assessment of anxiety states by rating. J Neurol Neurosurg Psychiatry 1960;23:50-55
29. Cleary P, Guy W. Factor analysis of the Hamilton Depression Scale. Drugs Exp Clin Res 1977;1:115-120
30. Nelder JA, Wedderburn RWM. Generalized linear models. J R Stat Soc 1972;135:370-384
31. Robinson DS, Kayser A, Corcella J, et al. Panic attacks in outpatients with depression: response to antidepressant treatment. Psychopharmacol Bull 1985;21(3):562-567
32. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129-137
33. Quitkin FM, McGrath PJ, Stewart JW, et al. Atypical depression, panic attacks, and response to imipramine and phenelzine. Arch Gen Psychiatry 1990;47:935-941
34. Delini-Stula A, Mikkelsen H, Angst J. Therapeutic efficacy of antidepressants in agitated anxious depression-a meta-analysis of moclobemide studies. J Affect Disord 1995;35:21-30
35. Moon CAL, Jago LW, Wood K, et al. A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associated anxiety in general practice. J Psychopharmacol 1994;8(3):171-176
36. Tollefson GD, Holman SL, Sayler ME, et al. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 1994;55(2):50-59
37. Marchesi C, Ceccherininelli A, Rossi A, et al. Is anxious-agitated major depression responsive to fluoxetine? A double-blind comparison with amitriptyline. Pharmacopsychiatry 1998;31:216-221
38. Simon GE, Heiligenstein JH, Grothaus L, et al. Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine. J Clin Psychiatry 1998;59(2):49-55
39. Versiani M, Ontiveros A, Mazzotti G, et al. Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison. Int Clin Psychopharmacol 1999;14(6):321-327
40. Hoehn-Saric R, Ninan P, Black DW, et al. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry 2000;57(1):76-82
41. Fawcett J, Marcus RN, Anton SF, et al. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 1995;56(suppl 6):37-42
42. Zajecka JM. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. J Clin Psychiatry 1996;57(suppl 2):10-14
43. Papakostas GI, Nutt DJ, Hallett LA, et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 2006;60(12):1350-1355